Rising India, Inc (OTCMKTS:RSII) is a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. The company is diversified into other areas, but we’re most interested in its current plans to take advantage of cannabis in the state of Ohio.
The passing of Ohio House Bill 523 officially made medical marijuana legal in September of 2016, but it is only now that the state is beginning issuance of medical marijuana licenses. RSII has been planning for this, and intends to become a player on the Ohio medical cannabis scene.
Rising India, Inc (OTCMKTS:RSII)’s Rising Bioscience subsidiary announced that its medical marijuana laboratory in Ohio is close to completion in line with the State of Ohio issuing medical marijuana licenses.
“Now that Ohio is beginning to issue licenses, we plan on being fully operational in our medical marijuana laboratory, which will focus on research, development, licensing and manufacturing of innovative products in the Cannabis space dedicated to serving patients with the highest standards,” stated COO Arthur Hall.
“We are also thrilled to announce that included in a line of medical cannabis products, the company is debuting Cannophen™, a revolutionary product we’ve been developing for some time now. Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures. This allows patients to take their medicine by swallowing a flavorless capsule, just like any other oral medication. We are also pleased to announce a new medical marijuana version of the TSW pain cream containing Cannabidiol (CBD).”
Hall added, “There has never been any proper